Studies on Osteogenesis Imperfecta
Bisphosphonate Therapy
  1. Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 2005;37:295-302.
  2. Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R, Mao C, Rauch F, Maes A, Larson P, Deutsch P, Glorieux FH. Single dose pharmacokinetics and short-term tolerability of alendronate 35- and 70-mg tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005;40:4051-4056.
  3. Munns C, Rauch F, Travers R, Glorieux FH. The effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res 2005;20:1235-1243.
  4. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377-1385.
  5. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis. J Bone Miner Res 2004;19:1191-1193.
  6. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377-1385.
  7. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004;35:231-234.
  8. Munns CF, Rauch F, Ward L, Glorieux FH. Effect of prenatal pamidronate therapy on maternal and fetal outcome: A report of two cases. J Bone Miner Res 2004;19:1742-1745.
  9. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-1786.
  10. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111:10 30-6.
  11. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003;111:e601-3.
  12. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism. J Clin Endocrinol Metab 2003;88:986-92.
  13. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18:610-4.
  14. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 2003;12:77-87.
  15. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110:1293-9.
  16. Glorieux FH. The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14 Suppl 6:1491-5.
  17. Glorieux FH. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 2000;13 Suppl 2:989-92.
  18. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
  19. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
Novel OI Types
  1. Munns CF, Rauch F, Travers R, Glorieux FH. Three children with lower limb fractures and a mineralization defect: A novel bone fragility disorder? Bone 2004;35:1023-1028.
  2. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002;31:12-8.
  3. Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, Roughley PJ, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002;31:19-25.
  4. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30-8.
  5. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000;15:1650-8.
Other OI Topics
  1. Rauch F. Bone growth in length and width: The Yin and Yang of bone stability. J Musculoskelet Neuronal Interact 2005;5:194-201.
  2. Ward LM, Rauch F, White KE, Filler G, Matzinger MA, Letts M, Travers R, Econs MJ, Glorieux FH. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF23-producing tumour of the distal ulna. Bone 2004;34:905-911.
  3. Ward LM, Rauch F, Travers R, Roy M, Montes J, Chabot G, Glorieux FH. Osteopathia striata with cranial sclerosis: clinical, radiological and bone histological findings in an adolescent girl. Am J Med Genet 2004;129A:8-12.

  4. Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta - clinical and molecular diversity. Eur Cell Mater 2003;5:41-47.
  5. Glorieux FH. Osteogenesis imperfecta. A disease of the osteoblast. Lancet 2001;358 Suppl:S45.
  6. Ward LM, Lalic L, Roughley PJ, Glorieux FH. Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV. Hum Mutat 2001;17:434.
  7. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000;26:581-9.
  8. Jones SJ, Glorieux FH, Travers R, Boyde A. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging. Calcif Tissue Int 1999;64:8-17.
  9. Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999;64:185-90.